TSTom J. J. Schirris

Tom J. J. Schirris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tom J. J. Schirris has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unlocking mitochondrial drug targets: The importance of mitochondrial transport proteins

    by Charlotte A. Hoogstraten, Tom J. J. Schirris, Frans G. M. Russel

    A disturbed mitochondrial function contributes to the pathology of many common diseases. These organelles are therefore important therapeutic targets. On the contrary, many adverse effects of drugs can be explained by a mitochondrial off‐target effect, in particular, due to an interaction with carrier proteins in the inner membrane. Yet this class of transport proteins remains underappreciated and understudied. The aim of this review is to provide a deeper understanding of the role of mitochondrial carriers in health and disease and their significance as drug targets. We present literature‐based evidence that mitochondrial carrier proteins are associated with prevalent diseases and emphasize their potential as drug (off‐)target sites by summarizing known mitochondrial drug–transporter interactions. Studying these carriers will enhance our knowledge of mitochondrial drug on‐ and off‐targets and provide opportunities to further improve the efficacy and safety of drugs.


  • Open Access

    Metabolic impact of genetic and chemical ADP/ATP carrier inhibition in renal proximal tubule epithelial cells

    by Charlotte A. Hoogstraten, Maaike M. E. Jacobs, Guido de Boer, Melissa A. E. van de Wal, Werner J. H. Koopman, Jan A. M. Smeitink, Frans G. M. Russel, Tom J. J. Schirris

    Mitochondrial dysfunction is pivotal in drug-induced acute kidney injury (AKI), but the underlying mechanisms remain largely unknown. Transport proteins embedded in the mitochondrial inner membrane form a significant class of potential drug off-targets. So far, most transporter-drug interactions have been reported for the mitochondrial ADP/ATP carrier (AAC). Since it remains unknown to what extent AAC contributes to drug-induced mitochondrial dysfunction in AKI, we here aimed to better understand the functional role of AAC in the energy metabolism of human renal proximal tubular cells. To this end, CRISPR/Cas9 technology was applied to generate AAC3−/− human conditionally immortalized renal proximal tubule epithelial cells. This AAC3−/− cell model was characterized with respect to mitochondrial function and morphology. To explore whether this model could provide first insights into (mitochondrial) adverse drug effects with suspicion towards AAC-mediated mechanisms, wild-type and knockout cells were exposed to established AAC inhibitors, after which cellular metabolic activity and mitochondrial respiratory capacity were measured. Two AAC3−/− clones showed a significant reduction in ADP import and ATP export rates and mitochondrial mass, without influencing overall morphology. AAC3−/− clones exhibited reduced ATP production, oxygen consumption rates and metabolic spare capacity was particularly affected, mainly in conditions with galactose as carbon source. Chemical AAC inhibition was stronger compared to genetic inhibition in AAC3−/−, suggesting functional compensation by remaining AAC isoforms in our knockout model. In conclusion, our results indicate that ciPTEC-OAT1 cells have a predominantly oxidative phenotype that was not additionally activated by switching energy source. Genetic inhibition of AAC3 particularly impacted mitochondrial spare capacity, without affecting mitochondrial morphology, suggesting an important role for AAC in maintaining the metabolic spare respiration.


  • Open Access

    Determination of cytotoxicity following oxidative treatment of pharmaceutical residues in wastewater

    by Martien H.F. Graumans, Hedwig van Hove, Tom Schirris, Wilfred F.L.M. Hoeben, Maurice F.P. van Dael, Rob B.M. Anzion, Frans G.M. Russel, Paul T.J. Scheepers


  • Open Access

    Restoring cellular NAD(P)H levels by PPARα and LXRα stimulation to improve mitochondrial complex I deficiency

    by Sanne J.C.M. Frambach, Ria de Haas, Jan A.M. Smeitink, Frans G.M. Russel, Tom J.J. Schirris


  • Open Access

    Dissecting Drug-Induced Cytotoxicity and Metabolic Dysfunction in Conditionally Immortalized Human Proximal Tubule Cells

    by Charlotte A. Hoogstraten, Jan A. M. Smeitink, Frans G. M. Russel, Tom J. J. Schirris

    Fourteen to 26 percent of all hospitalized cases of acute kidney injury are explained by drug-induced toxicity, emphasizing the importance of proper strategies to pre-clinically assess renal toxicity. The MTT assay is widely used as a measure of cell viability, but largely depends on cellular metabolic activity. Consequently, MTT as a single assay may not be the best way to assess cytotoxicity of compounds that reduce mitochondrial function and cellular metabolic activity without directly affecting cell viability. Accordingly, we aim to highlight the limitations of MTT alone in assessing renal toxicity of compounds that interfere with metabolic activity. Therefore, we compared toxic effects observed by MTT with a fluorescent assay that determines compromised plasma membrane permeability. Exposure of proximal tubule epithelial cells to nephrotoxic compounds reduced cellular metabolic activity concentration- and time-dependently. We show that compared to our fluorescence-based approach, assessment of cellular metabolic activity by means of MTT provides a composite readout of cell death and metabolic impairment. An approach independent of cellular metabolism is thus preferable when assessing cytotoxicity of compounds that induce metabolic dysfunction. Moreover, combining both assays during drug development enables a first discrimination between compounds having a direct or indirect mitochondrial toxic potential.


  • Disorders of Mitochondrial Carriers

    by Tom J. J. Schirris, Jan A. M. Smeitink, Frans G. M. Russel

  • Open Access

    Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention

    by Melissa A E van de Wal, Merel J W Adjobo-Hermans, Jaap Keijer, Tom J J Schirris, Judith R Homberg, Mariusz R Wieckowski, Sander Grefte, Evert M van Schothorst, Clara van Karnebeek, Albert Quintana, et al.

    Mitochondria are small cellular constituents that generate cellular energy (ATP) by oxidative phosphorylation (OXPHOS). Dysfunction of these organelles is linked to a heterogeneous group of multisystemic disorders, including diabetes, cancer, ageing-related pathologies and rare mitochondrial diseases. With respect to the latter, mutations in subunit-encoding genes and assembly factors of the first OXPHOS complex (complex I) induce isolated complex I deficiency and Leigh syndrome. This syndrome is an early-onset, often fatal, encephalopathy with a variable clinical presentation and poor prognosis due to the lack of effective intervention strategies. Mutations in the nuclear DNA-encoded NDUFS4 gene, encoding the NADH:ubiquinone oxidoreductase subunit S4 (NDUFS4) of complex I, induce ‘mitochondrial complex I deficiency, nuclear type 1’ (MC1DN1) and Leigh syndrome in paediatric patients. A variety of (tissue-specific) Ndufs4 knockout mouse models were developed to study the Leigh syndrome pathomechanism and intervention testing. Here, we review and discuss the role of complex I and NDUFS4 mutations in human mitochondrial disease, and review how the analysis of Ndufs4 knockout mouse models has generated new insights into the MC1ND1/Leigh syndrome pathomechanism and its therapeutic targeting.


  • Open Access

    The ketogenic diet as a therapeutic intervention strategy in mitochondrial disease

    by Changbo Qu, Jaap Keijer, Merel J.W. Adjobo-Hermans, Melissa van de Wal, Tom Schirris, Clara van Karnebeek, Yihang Pan, Werner J.H. Koopman


  • Open Access

    Dissecting drug-induced in vitro cytotoxicity and metabolic dysfunction in conditionally immortalized human proximal tubule cells

    by Charlotte A. Hoogstraten, Jan A.M. Smeitink, Frans G.M. Russel, Tom J.J. Schirris

    Acute kidney injury accounts for 20% of all hospitalized adults, and 14 to 26% is drug-induced, emphasizing the importance of proper nephrotoxicity assessment. The ‘gold standard’ MTT assay is widely used to measure cell viability, but depends on cellular metabolic activity. Consequently, MTT may not be most optimal to assess cytotoxicity, as nephrotoxicity often involves mitochondrial dysfunction. We compared MTT with a direct cell death assay based on a compromised plasma membrane permeability. Mature conditionally immortalized proximal tubule epithelial cells were dose- (0.1-1,000 µM) and time- (0.5, 1, 2, 4, 8 and 24 hours) dependently exposed to a selection of prototypic nephrotoxicants. Dose-dependent reductions in cellular metabolic activity were stronger compared to declines in fluorescence-based cell death, most prominently for cisplatin (1.6 ± 2.0% and 68 ± 4% (mean ± SEM), respectively) and chloroacetaldehyde (2.13 ± 0.05% and 61.0 ± 0.8%). Similar, but more pronounced time-dependent effects were observed, particularly for sanguinarine. We show that assessing cellular metabolic activity by MTT provides a composite readout of cellular metabolic activity and cell death. A nuclear staining approach is preferable when assessing nephrotoxicity of metabolically active compounds. We recommend both assays during drug development to discriminate between metabolically active versus non-active compounds.


  • Open Access

    Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition

    by Stephany Jaiquel Baron, Martin S. King, Edmund R.S. Kunji, Tom J.J. Schirris

    An increasing number of commonly prescribed drugs are known to interfere with mitochondrial function, causing cellular toxicity, but the underlying mechanisms are largely unknown. Although often not considered, mitochondrial transport proteins form a significant class of potential mitochondrial off-targets. So far, most drug interactions have been reported for the mitochondrial ADP/ATP carrier (AAC), which exchanges cytosolic ADP for mitochondrial ATP. Here, we show inhibition of cellular respiratory capacity by only a subset of the 18 published AAC inhibitors, which questions whether all compound do indeed inhibit such a central metabolic process. This could be explained by the lack of a simple, direct model system to evaluate and compare drug-induced AAC inhibition.